What Vertex Pharmaceuticals (VRTX)'s Pancreas Recovery Data Means For Shareholders

Vertex Pharmaceuticals recently presented interim data from its ALYFTREK regimen in children aged 2 to 5 with cystic fibrosis, showing restored exocrine pancreatic function in some patients and enabling a portion to stop lifelong pancreatic enzyme replacement therapy. The reported recovery of pancreatic function in a condition long viewed as permanently damaging points to a potential shift in how early cystic fibrosis treatment might affect long term organ health and future standard of care...